Transition of Substance-Induced Psychoses to Schizophrenia Transition of Substance-Induced Psychoses to Schizophrenia
What proportion of people with substance-induced psychoses transition to schizophrenia? What might be potential moderators for risk?Schizophrenia Bulletin
Conditions: Schizophrenia; Parkinson Disease; Hallucinations Intervention: Sponsors: University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridgeshire and Peterborough NHS Foundation Trust Not yet recruiting
Publication date: Available online 22 May 2020Source: Progress in Neuro-Psychopharmacology and Biological PsychiatryAuthor(s): Xuemin Jian, Jianhua Chen, Zhiqiang Li, Aamir Fahira, Weihuan Shao, Juan Zhou, Ke Wang, Yanqin Wen, Jinmai Zhang, Qiangzhen Yang, Dun Pan, Zhuo Wang, Yongyong Shi
Publication date: Available online 22 May 2020Source: Journal of Clinical NeuroscienceAuthor(s): Guillaume Barbalat, Nicolas Franck
Conclusion: Our findings provide insight into the role of hypoconnectivity of the ventral corticostriatal system in people with schizophrenia. PMID: 32436671 [PubMed - as supplied by publisher]
Authors: Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, Yagoda S, Bidollari I, Keane E, Cash E Abstract OBJECTIVE: Evaluate efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) with 1-day initiation during hospitalization for acute exacerbation of schizophrenia followed by transition to outpatient care. METHODS: The phase 3b double-blind Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness (ALPINE) study was conducted from November 2017 to March 2019. Adults with acute schizophrenia according to DSM-5 criteria were randomized (1:1) to AL (AL NanoCrystal Dis...
Publication date: September 2020Source: Schizophrenia Research: Cognition, Volume 21Author(s): Nathan Caruana, Christine Inkley, Marwa El Zein
CONCLUSIONS: There was no association between SNCA polymorphisms and schizophrenia in the North Han Chinese population, and the ATT haplotype may be a susceptibility factor for schizophrenia. PMID: 32432761 [PubMed - in process]
Publication date: Available online 21 May 2020Source: Neuroscience LettersAuthor(s): Ali Bani-Fatemi, Anvesh Roy, Nasia Dai, Oluwagbenga Dada, Christopher Adanty, Lavaniya Kiruparajah, Nathan Kolla, John Strauss, Clement Zai, Ariel Graff, Philip Gerretsen, Vincenzo De Luca
In this study, we explored the association between olanzapine-induced weight gain and metabolic effects with increased appetite. Drug-naïve, first-episode schizophrenia patients were treated with olanzapine for 12 weeks. Assessments included time to increased appetite, body weight, body mass index, biochemical indicators of blood glucose and lipids, proportion of patients who gained more than 7% or 10% of their baseline weight upon treatment conclusion, patients who developed dyslipidemia, and Positive and Negative Syndrome Scale scores. In total, 33 patients with schizophrenia receiving olanzapine were enrolled and 3...
AbstractPurpose of ReviewCannabis exposure during critical windows of development may have intergenerational physiological consequences disrupting epigenetic programming and marks. This review examines the literature relating to pre-gestational and prenatal cannabinoid exposure and its effect on genes and molecular pathways related to the development of psychiatric disease.Recent FindingsDevelopmental cannabis exposure alters epigenetic processes with functional gene consequences. These include potentially heritable alterations in genes and molecular pathways critical for brain development and associated with autism spectr...